PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Impaired clearance, not overproduction of toxic proteins, may underlie Alzheimer’s disease

2010-12-10
(Press-News.org) In Alzheimer's disease, a protein fragment called beta-amyloid accumulates at abnormally high levels in the brain. Now researchers funded by the National Institutes of Health have found that in the most common, late-onset form of Alzheimer's disease, beta-amyloid is produced in the brain at a normal rate but is not cleared, or removed from the brain, efficiently. In addition to improving the understanding of what pathways are most important in development of Alzheimer's pathology, these findings may one day lead to improved biomarker measures for early diagnosis as well as a new approach to treating this devastating disorder.

Many believe that accumulation of abnormal levels of beta-amyloid in the brain initiates a cascade of events leading to the death of brain cells and ultimately to dementia. In the rare, early-onset forms of Alzheimer's that are linked to genetic mutations there is a marked increase in beta-amyloid production. In the more common, late-onset form of Alzheimer's, the mechanisms leading to increased beta-amyloid levels are not well understood.

The study, published in Science, was led by senior author Randall Bateman, M.D., an assistant professor of neurology at Washington University in St. Louis. Dr. Bateman and his colleagues previously reported an innovative procedure to measure beta-amyloid levels over time in cerebrospinal fluid (CSF) – the fluid that bathes the brain. In the new study, the researchers used that procedure to measure beta-amyloid production and clearance rates in study volunteers with Alzheimer's disease and in age-matched volunteers free of the disease.

"These findings may help point us toward better diagnostic tests and effective therapies. The next question is what is causing the decreased clearance rate," said Dr. Bateman.

Prior studies in animals suggest several possible explanations for the slower clearance of beta-amyloid in late-onset Alzheimer's. One possibility is that as beta-amyloid accumulates, it acts as a sink for more of the protein, trapping it within the brain. The researchers believe that sorting out these mechanisms is likely to help speed the development of new drugs for the disease.

"Abnormal protein deposits within the brain are a hallmark not only of Alzheimer's disease, but of many neurological disorders. With knowledge about how these proteins accumulate, we may be able to slow that process and reduce the damage to the brain," said Roderick Corriveau, Ph.D., a program director at NIH's National Institute of Neurological Disorders and Stroke (NINDS).

Dr. Bateman and his colleagues measured beta-amyloid levels in the CSF of 12 patients with late-onset Alzheimer's and 12 cognitively normal individuals. The participants' average age was 74. Their CSF was sampled every hour for 36 hours, via a one-time lumbar puncture. Throughout the procedure, they were encouraged to stay in bed.

During the first nine hours, the participants received an IV drip containing leucine, a protein building block, which had been labeled with a non-radioactive isotope. By measuring the amount of labeled beta-amyloid by mass spectroscopy over time, the researchers were able to calculate how fast it was produced in the participants' brains and how fast it was cleared. The clearance of beta-amyloid was about 30 percent slower in individuals with Alzheimer's disease than in cognitively normal individuals. This is consistent with previous findings that beta-amyloid is decreased in the CSF of people with Alzheimer's and in those with mild cognitive impairment at high risk of developing the disease.

Dr. Bateman's procedure has enabled researchers to investigate the effects of new drugs aimed at tamping down beta-amyloid levels. The procedure also could be a starting point toward a shorter, simpler test – perhaps a blood test – that measures beta-amyloid clearance rates to detect Alzheimer's prior to the first symptoms.

"This study is significant in that it reports the first measurement of beta-amyloid production and clearance in Alzheimer's," said Marcelle Morrison-Bogorad, Ph.D., director of the Division of Neuroscience at the National Institute on Aging (NIA). "For years scientists believed that it was the overproduction of beta-amyloid that led to its accumulation in the brain. These new findings shift the emphasis to clearance of beta-amyloid. This may lead to development of a diagnostic test as well as identification of new therapeutic targets."

###Alzheimer's disease is the most common cause of dementia in older adults, and affects as many as 5.1 million Americans. In the late-onset type of Alzheimer's disease, symptoms usually appear after age 65.

The study was supported in part by NINDS, NIA, the National Center for Research Resources (NCRR), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), all components of NIH. Dr. Bateman is an investigator at the Charles F. and Joanne Knight Alzheimer's Disease Research Center (ADRC) and the Hope Center for Neurological Disorders at Washington University.

Reference: Mawuenyega, KG et al. "Decreased clearance of amyloid-beta in the CNS of humans with Alzheimer's disease." Science, published online December 9, 2010.

NINDS (www.ninds.nih.gov) is the nation's leading funder of research on the brain and nervous system. The NINDS mission is to reduce the burden of neurological disease – a burden borne by every age group, by every segment of society, by people all over the world.

NIA (www.nia.nih.gov) leads the federal government effort conducting and supporting research on aging and the health and well-being of older people. NIA provides information on age-related cognitive change and neurodegenerative disease specifically at its Alzheimer's Disease Education and Referral (ADEAR) Center at www.nia.nih.gov/Alzheimers.

NCRR (www.ncrr.nih.gov) provides laboratory scientists and clinical researchers with the resources and training they need to understand, detect, treat and prevent a wide range of diseases.

NIDDK (www.niddk.nih.gov) conducts and supports basic and clinical research on: diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition, and obesity; and kidney, urologic and hematologic diseases.

The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

END



ELSE PRESS RELEASES FROM THIS DATE:

Gene knockout shows potential for diabetes-related heart failure

2010-12-10
Silencing the TLR4 gene can stop the process which may lead to cardiovascular disease in diabetic patients. Researchers writing in BioMed Central's open access Journal of Translational Medicine carried out a series of in vitro tests which demonstrated that TLR4 plays a critical role in hyperglycaemic cardiac apoptosis, and that silencing the gene using specific small interfering RNA (siRNA) can prevent it. Wei-Ping Min, from the University of Western Ontario, Canada, worked with a team of researchers to perform the tests in cells taken from diabetic mice. He said, "We ...

Plant disease 'stealth bomber' tactics subverted to tackle hundreds of plant pathogens

2010-12-10
Research, led by the University of Warwick, The Sainsbury Laboratory, and Virginia Polytechnic Institute and State University (Virginia Tech), has sequenced the genome of a plant disease causing organism revealing that it acts like a "stealth bomber of plant pathogens". The research has uncovered the tactics used to sneak past the plant's immune defences. That same discovery also provides tools for researchers to identify the components of the plant immune system and devise new ways to prevent disease. The research at the University of Warwick, the Sainsbury Laboratory ...

Identifying lung cancer gene markers shows promise in identifying patients needing chemo

2010-12-10
Cancer researchers have identified six gene markers present in early stage non-small cell lung cancer (NSCLC) that show promise in helping oncologists better identify which tumors will relapse after curative surgery, according to a study presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago. Lung cancer is the leading ...

Researchers track the impacts of depression during pregnancy

2010-12-10
ANN ARBOR, Mich. — The cocktail of hormones cascading through depressed mothers' bodies may play an important role in the development of their unborn children's brains. A higher level of depression in mothers during pregnancy was associated with higher levels of stress hormones in their children at birth, as well as with other neurological and behavioral differences, a University of Michigan-led study found. "The two possibilities are that they are either more sensitive to stress and respond more vigorously to it, or that they are less able to shut down their stress ...

Exposure to North Dakota road material may increase risk of lung cancer

2010-12-10
New data shows that people exposed to the mineral erionite found in the gravel of road materials in North Dakota may be at significantly increased risk of developing mesothelioma, a type of lung cancer most often associated with asbestos exposure, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago. Erionite ...

Personalized molecular therapy shows promising results for people with advanced lung cancer

2010-12-10
A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago. Epigenetics therapy is an approach designed to control the expression of good and bad genes ...

Adding ipilimumab to standard chemotherapy treatment for late-stage lung cancer may improve survival

2010-12-10
– Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago. Paclitaxel/carboplatin are commonly ...

Non-invasive SRT as good as surgery for elderly patients with early lung cancer

2010-12-10
A new study shows that a new type of targeted radiation therapy called stereotactic radiation therapy is just as good as surgery for patients aged 75 and older with early-stage lung cancer, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago. In this study, researchers compared two treatments ...

Weekend and public holiday admissions increased the risk of hospital deaths by up to 41 percent

2010-12-10
Patients treated by Welsh (UK) hospitals for upper gastrointestinal (GI) bleeding were 41% more likely die if they were admitted on a public holiday and 13% more likely if it was at the weekend, according to research in the January issue of Alimentary Pharmacology and Therapeutics. Researchers who analysed the records of 22,299 people admitted a total of 24,421 times between 1999 and 2007 also found that admissions, but not death rates, were significantly influenced by social deprivation. "The higher death rates for weekend and public holiday admissions could not ...

Greedy algorithms best for multiple targets

2010-12-10
What algorithms should an air defense system work with? Particle swarm algorithms if there are ten targets to be hit. If there are more than ten targets, greedy algorithms work best. These findings are presented by researcher Fredrik Johansson at the Informatics Research Centre, University of Skövde, in Sweden. So-called TEWA systems (Threat Evaluation & Weapon Allocation) are used to protect strategic targets from enemy attacks, such as an airfield that needs to be protected from incoming missiles. The systems discover threats, evaluates the threats, and aims the defender's ...

LAST 30 PRESS RELEASES:

Students with multiple marginalized identities face barriers to sports participation

Purdue deep-learning innovation secures semiconductors against counterfeit chips

Will digital health meet precision medicine? A new systematic review says it is about time

Improving eye tracking to assess brain disorders

Hebrew University’s professor Haitham Amal is among a large $17 million grant consortium for pioneering autism research

Scientists mix sky’s splendid hues to reset circadian clocks

Society for Neuroscience 2024 Outstanding Career and Research Achievements

Society for Neuroscience 2024 Early Career Scientists’ Achievements and Research Awards

Society for Neuroscience 2024 Education and Outreach Awards

Society for Neuroscience 2024 Promotion of Women in Neuroscience Awards

Baek conducting air quality monitoring & simulation analysis

Albanese receives funding for scholarship grant program

Generative AI model study shows no racial or sex differences in opioid recommendations for treating pain

New study links neighborhood food access to child obesity risk

Efficacy and safety of erenumab for nonopioid medication overuse headache in chronic migraine

Air pollution and Parkinson disease in a population-based study

Neighborhood food access in early life and trajectories of child BMI and obesity

Real-time exposure to negative news media and suicidal ideation intensity among LGBTQ+ young adults

Study finds food insecurity increases hospital stays and odds of readmission 

Food insecurity in early life, pregnancy may be linked to higher chance of obesity in children, NIH-funded study finds

NIH study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry

New study reveals changes in the brain throughout pregnancy

15-minute city: Why time shouldn’t be the only factor in future city planning

Applied Microbiology International teams up with SelectScience

Montefiore Einstein Comprehensive Cancer Center establishes new immunotherapy institute

New research solves Crystal Palace mystery

Shedding light on superconducting disorder

Setting the stage for the “Frankfurt Alliance”

Alliance presents final results from phase III CABINET pivotal trial evaluating cabozantinib in advanced neuroendocrine tumors at ESMO 2024 and published in New England Journal of Medicine

X.J. Meng receives prestigious MERIT Award to study hepatitis E virus

[Press-News.org] Impaired clearance, not overproduction of toxic proteins, may underlie Alzheimer’s disease